Digital & Innovation
Artificial intelligence predicts risk for lung cancer from chest x-rays

Digital & Innovation: A deep learning model, a form of artificial intelligence (AI), was more accurate than the current clinical standard at predicting a person’s 12-year risk of developing lung cancer.
The model’s predictions are based on chest radiograph images (CXRs) and basic demographic data (age, sex, and current smoking status) commonly available in electronic health records (EHRs). The findings are published in Annals of Internal Medicine.
Lung cancer screening with chest computed tomography (CT) scans can prevent lung cancer death. However, Medicare’s current standard to determine who is eligible for lung cancer screening CT misses most lung cancers. Furthermore, lung cancer screening participation is poor, with an estimated less than 5 percent of screening-eligible persons being screened.
Researchers from Massachusetts General Hospital developed a convolutional neural network (CXR-LC) that predicts long-term incident lung cancer based on a chest x-ray image using 41,856 people from a large multicenter trial of lung cancer screening with chest x-rays (Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial).
The final model was validated in 5,615 additional PLCO participants and 5,493 persons from a second trial, the National Lung Screening Trial (NLST). The deep learning model performed better than the Medicare lung cancer screening criteria, the current clinical standard, missing 31% fewer lung cancers while screening the same number of people.
News - MedTech & Diagnostics
PL reforms deliver $1 billion in savings but patients are yet to see the benefit
The final evaluation of the Prescribed List (PL) reforms has delivered a mixed verdict on one of the private health […]
MoreNews - Pharmaceuticals
Lilly global CEO takes aim at PBS over Mounjaro price fight
Eli Lilly’s global CEO has accused the Pharmaceutical Benefits Scheme (PBS) of failing to keep pace with a new era […]
MoreNews - Pharmaceuticals
Cheap old drug enters MS PBS review as access battle continues
The Department of Health has outlined the scope and timelines of the Rapid review of PBS medicines for relapsing-remitting multiple […]
MoreNews - MedTech & Diagnostics
The piss test, missed diagnoses and the dialysis crunch: Kidney Action Week
Kidney Health Australia is taking an unconventional approach to a serious health issue, launching a national media campaign during Kidney […]
More